Patent cliffs & loss of exclusivity
Aquestive Therapeutics is a publicly traded pharmaceutical company headquartered in Warren, New Jersey, with manufacturing operations in Portage, Indiana. Its predecessor MonoSol Rx was formed in 2004; the company traces its drug-delivery platform operations to 2005. It develops oral-film medicines and delivery technologies, including PharmFilm and the AdrenaVerse epinephrine-prodrug platform, and manufactures licensed medicines for pharmaceutical partners. Its Anaphylm sublingual-film candidate remains investigational under FDA review. Dan Barber leads Aquestive as President and CEO.
| CAGE Code | 5MZL2 |
|---|---|
| Legal Name | Aquestive Therapeutics, Inc. |
| Company Operating Status | Active |
| Contact Page URL | https://aquestive.com/#contact-aquestive |
| Crunchbase URL | https://www.crunchbase.com/organization/monosolrx |
| Email format | {f}{last} |
| Full Address | 30 Technology Drive, Warren, New Jersey 07059, US |
| LinkedIn URL | https://www.linkedin.com/company/aquestive |
Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.